Phase 3Completed

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.

Sponsor
Catalysis SL (Industry)
Enrollment
76 enrolled
Conditions
External Anogenital Warts
Interventions
Glizigen + Viusid; Placebo
Ages
children, adults
Registry
NCT01111344

Full record on ClinicalTrials.gov

From the registry

The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in the treatment of external anogenital warts in children and adolescents. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons to be recruited and randomized for the study is 76. Variables to be assessed will be: time to disappearance of lesions, reduction of the number of lesions and change in the aspect of lesions.

Primary outcomes

  • Time to lesion regression

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered